Noven is a fully-integrated specialty pharmaceutical company with industry-leading transdermal expertise

About Noven - Timeline

Noven – 1987 to Today

Noven's history began in 1987 in Miami, Florida with the mission to develop differentiated prescription transdermal drug delivery systems (patches) to benefit patients across a range of therapeutic conditions. Today, Noven is the U.S. platform for Hisamitsu, the world's largest patch manufacturer, with fully-integrated R&D, clinical, manufacturing, and sales functions offering prescription products in the areas of women's health and central nervous system (CNS) disorders.

July 2016
Brisdelle® and Pexeva® acquired by Sebela Pharmaceuticals
February 2015
New Minivelle® (Estradiol Transdermal System) 0.025 mg/day Dose Now Available by Prescription in U.S. Pharmacies
November 2013
Launch of Brisdelle®
June 2013
Brisdelle® approved by the FDA
January 2013
Noven Women's Health team launches Minivelle®
December 2012
Noven acquires Minivelle®, establishes Women's Health sales team
October 2012
Minivelle®, world's smallest estrogen patch, approved by FDA
2011
Noven's Northeast operations consolidated in Empire State Building co-headquarters
2010
Noven reacquires Daytrana® from Shire
2010
Hisamitsu Carlsbad facility integrated with Noven operations
2009
Noven acquired by Hisamitsu Pharmaceuticals; public company status concludes
2007
Noven acquires JDS Pharmaceuticals, expanding its portfolio and sales capabilities
2006
Shire and Noven launch Daytrana®
2003
Shire licenses Noven's Daytrana® patch for ADHD
1999
Launch of Vivelle-Dot®, the world's smallest estrogen patch at the time
1998
Launch of CombiPatch®, the first combination (two-drug) patch
1998
Formation of Novogyne joint venture in Women's Health
1996
Launch of Vivelle®, the first adhesive matrix estrogen patch
1988
Noven becomes a public company
1987
Noven founded by Steven Sablotsky
Minivelle Package Japan USA Flags Daytrana PackageVivelle Dot Vivelle Conveyor Vivelle Dot Approval Noven's Building Noven Company

Fast Facts

Core Business:

Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.

Year of Incorporation:

1987

Employees:

Over 325

Chief Executive Officer:

Jeff Mihm

Media, General Business
& Other Inquiries:

Tel: 305-253-1916
CorporateAffairs@noven.com

Partnering and Other Business Development Opportunities

Tel: 551-233-2700
BusDev@noven.com

Physican Payment
Sunshine Act Inquiries:

Aggspend@noven.com

Employment Inquiries:

Rory Kelly
Associate Director – Recruiting
Tel: 305-964-3588
Careers Page

Community Support:

Corporate Social Responsibility

Affiliated Companies:

Noven is a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. – bringing the benefits of patch therapy to patients around the world.